Patent Analysis
Patent Analysis
Sale
The allogeneic CAR T-cell market was valued at USD 0.87 billion in 2023. It is expected to grow at a CAGR of 15.6% for the forecast period of 2024-2032 and attain a market value of USD 3.24 billion by 2032. The market value is impacted by increased technical advancements as well as the rising incidence of cancer. The need for cutting-edge technologies owing to clearly offer broader patient access as compared to the autologous therapies due to premanufactured and off-the-shelf products is driving the rise in the number of patents in this industry.
The global allogeneic CAR T-cell patent landscape report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for global allogeneic CAR T-cell include patent distribution by time, geographical coverage, top IP player profiles, technological segmentation, and patent valuation.
A thorough examination of the patent portfolios of key players, covering aspects such as the number of patents, types of technologies patented, and trends over time. A detailed description of the companies granted with patents, analysis of the distribution of patents geographically, and information on key regions where patent filings are concentrated. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within allogeneic CAR T-Cell technologies.
For instance, CRISPR/Cas9 gene editing technology permits exact T cell modification for the need of inserting the CAR gene and conditionally editing other genes to increase safety, improve persistence or lessen immunological rejection.
Allogeneic CAR T-Cell (chimeric antigen receptor) therapy is a state-of-the-art cancer treatment that uses T cells from healthy donors. Thanks to genetic engineering, these T-cells express receptors that specifically target antigens in cancer cells. When compared to autologous CAR-T therapy (which makes use of the patient’s cells), this over-the-counter therapy enables quicker and more extensive treatment. Avoiding graft-versus-host disease (GvHD), which is commonly treated with gene editing, is one of the major.
Allogeneic CAR T-cell continues to evolve, driven by decreasing the cost of therapy making it more affordable and accessible. Its ability to deliver effective therapeutic results in combination with other therapies against cancer and other immune diseases, which is a driving factor for the market in forecasted period.
Technical Advancements and Product Launches are Expected to Augment the Market Growth
Universal donor CAR-T cells are engineered from healthy donors and designed to be used across multiple patients, providing an off-the-shelf solution. Allogeneic CAR T-cell treatment options are getting advanced by the research and development of market leaders to treat diseases like cancer.
For instance, in January 2023, a well-known company, Allogene Therapeutic’s ALLO-501, an Allogeneic CAR T-cell therapy targeting CD19 (a protein present on the surface of B-cell tumors) showed promising results in its phase-1 clinical trial when used for the treatment of non-Hodgkin lymphoma. The ability to develop a ready-to-use therapy lowers production time and costs significantly in comparison to patient-specific (autologous) CAR-T treatments, increasing accessibility and scalability of the treatment.
Gene Editing Technologies to Enhance the Efficacy and Safety is Expected to Propel the Allogeneic CAR-T Cell Industry Growth
Enhancing the safety and efficacy of allogeneic CAR T-cell therapies requires the application of CRISPR /Cas9 and other gene editing technologies. These technologies enable the precise modification of T-cells to target cancer and eliminate T-cell receptors (TCRs) that cause graft-versus-host disease (GvHD) more efficiently. Consequently, there is a decreased possibility of adverse reactions and safer, more efficient treatments.
The report will cover the following sections in detail:
Breakup by Type
Breakup by Target Indication
Breakup by Target Antigen
Allogeneic CAR T-Cell investigations have been conducted with the chosen patent families based on the technology to which they pertain. This patent landscape report features various technologies present in the allogeneic CAR T-Cell market including zinc finger nucleases (ZFN), next-generation sequencing (NGS), clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 and transcription activator-like effector nucleases (TALEN). Next-generation sequencing (NGS) is used in allogeneic CAR-T Cell therapy to perform comprehensive quality control and genetic screening of engineered T-cells. This ensures that the modified T-cells meet all relevant safety and efficacy standards are free of accidental alterations and have the necessary genetic modifications before being infused into patients.
The detailed technological data will be provided for all specified segments classified in this report.
This study includes an analysis of key players in the global allogeneic CAR T-Cell patent landscape, detailing their patent portfolios, patent issuance trends over time, geographic coverage, active patents in various technical segments, and financial analysis. After this patent profile overview, we look at the technological content found in their main patents.
Among the players with allogeneic CAR T-cell patent families, pre-existing new entrants have been identified. These companies can be either established companies or startups developing their first technology in the field. These innovative companies can become a future key player in healthcare, attracting investments from major corporations.
Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:
A biopharmaceutical company renowned for developing innovative cancer, cardiovascular, and immunology treatments. BMS is working hard to improve its Allogeneic CAR-T Cell (chimeric antigen receptor) therapy pipeline. The company wants to create off-the-shelf CAR-T cell treatments that will improve accessibility and efficacy for cancer patients by employing cutting-edge gene editing technologies.
Compugen LTD
Leading therapeutic development company focused on mmune-oncology discovery at the clinical stage. This company uses its computational discovery platforms and in-depth understanding of the tumour microenvironment to collaborate with other biopharmaceutical companies on cutting-edge therapies, such as Allogeneic CAR-T cell therapies, to improve cancer treatment. Development of biological drugs and the identification of new drug targets are its two main areas of expertise.
Other players in the market include Artiva Biotherapeutics Inc., Poseida Therapeutics, Inc., Nanjing Beiheng Biological Technology Co., Ltd., and NantCell, Inc., among others.
Studying the intellectual property (IP) position and strategy of players in the global allogeneic CAR T- cell patent landscape report is crucial for several reasons:
Scope of the Report | Details |
Analysis by Type |
|
Target Indication |
|
Target Antigen |
|
Key Players Mentioned | Artiva Biotherapeutics Inc⯠Poseida Therapeutics, Inc. Nanjing Beiheng Biological Technology Co., Ltd. NantCell, Inc. Bristol Mayer Squibb Company Compugen LTD Others |
Geographies Covered | North America Europe Asia Pacific Others |
Global CAR-T Cell Therapy Market
Global Cell and Gene Therapy Market
Global Cancer Immunotherapy Market
Global Cancer Cryotherapy Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Introduction
2 Executive Summary
3 Global Allogenic CAR-T Cell Market Overview
3.1 Global Allogenic CAR-T Cell Market Historical Value (2017-2023)
3.2 Global Allogenic CAR-T Cell Market Forecast Value (2024-2032)
4 Global Allogenic CAR-T Cell Market Segmentation
4.1 Global Allogenic CAR-T Cell Market Share by Type
4.1.1 Market Overview
4.1.2 Stem Cell
4.1.3 Non-Stem Cell
4.2 Global Allogenic CAR-T Cell Market Share by Target Indication
4.2.1 Market Overview
4.2.2 Acute Lymphoblastic Leukemia
4.2.3 Diffuse Large B-cell Lymphoma
4.2.4 Follicular Lymphoma
4.2.5 Large B-cell Lymphoma
4.2.6 Mantle Cell Lymphoma
4.2.7 Others
4.3 Global Allogenic CAR-T Cell Market Share by Target Antigens
4.3.1 Market Overview
4.3.2 CD19
4.3.3 BCMA
4.3.4 CD20
4.3.5 CD19/22
4.3.6 Others
5 Global Market Dynamics
5.1 Market Drivers and Constraints
5.2 Porter’s Five Forces Analysis
5.3 PESTEL Analysis
5.4 Industry Events, Initiatives, and Trends
5.5 Value Chain Analysis
6 Global Allogenic CAR-T Cell Patent Landscape Analysis
6.1 Patent Distribution by Publication Year
6.2 Patent Distribution by Application Year
6.3 Patent Distribution by Priority Year
6.4 Analysis by Type of Patent
6.4.1 Granted Patents
6.4.2 Patent Application
6.4.3 Amended Application
6.4.4 Search Report
6.5 Analysis by Legal Status
6.5.1 Active
6.5.2 Pending
6.5.3 Expired/Discontinued
6.6 Analysis by Patent Jurisdiction
6.7 Analysis by Patent Age
6.8 Analysis by Cooperative Patent Classification (CPC) Codes
6.9 Average Time to Publish a Patent
6.9.1 By Entities
6.9.2 By Jurisdiction
6.9.3 By Technology
6.10 Analysis by Type of Entity (Academic and Non-Academic)
6.11 Analysis by Top Applicants
6.12 Analysis by Top Inventors
7 Global Allogenic CAR-T Cell Industry Patent Analysis by Technology
7.1 Total Patents by Top Technologies
7.2 Time Evolution of Patents by Technology
7.3 Emerging Technologies
7.4 Zinc Finger Nucleases (ZFN)
7.4.1 Time Evolution by Number of Patents
7.4.2 Time Evolution by Number of Patent Families
7.4.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.4.4 Analysis by Top Applicants
7.4.5 Analysis by Top Inventors
7.5 Transcription Activator-Like Effector Nucleases (TALEN)
7.5.1 Time Evolution by Number of Patents
7.5.2 Time Evolution by Number of Patent Families
7.5.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.5.4 Analysis by Top Applicants
7.5.5 Analysis by Top Inventors
7.6 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9
7.6.1 Time Evolution by Number of Patents
7.6.2 Time Evolution by Number of Patent Families
7.6.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.6.4 Analysis by Top Applicants
7.6.5 Analysis by Top Inventors
*Complete Technology list will be provided in the report.
8 EMR Patent Valuation Analysis
8.1 Assessment Methodology
8.2 High Value Patents
8.3 Medium Value Patents
8.4 Low Value Patents
9 Global Allogenic CAR-T Cell – Top 10 Players Patent Analysis
9.1 Top 10 Entities by Number of Patents
9.2 Analysis by Publication Year
9.3 Analysis by Application Year
9.4 Analysis by Priority Year
9.5 Analysis by Type of Patent
9.6 Analysis by Jurisdiction
9.7 Analysis by Cooperative Patent Classification (CPC) Codes
9.8 Analysis by Source of Innovation
9.9 Analysis by Forward and Backward Citations
9.10 Analysis by Legal Status
9.11 Analysis by Patent Age
9.12 Analysis by Key Inventors
9.13 Entity Dynamics
9.13.1 Analysis by Type of Player (Academic vs Non-Academic)
9.13.2 Analysis by Collaboration
9.13.3 Analysis by Technology
9.13.4 Newcomers
9.13.4.1 Start-up Companies
9.13.4.2 Established Companies
10 Patent Profile of Key Players
10.1 Artiva Biotherapeutics Inc
10.1.1 Product Portfolio
10.1.2 Patent Portfolio by Patent Families
10.1.3 Time Evolution of Patents
10.1.4 Geographical Patent Coverage
10.1.5 Patent Analysis by Technology
10.1.6 Patent News and Developments
10.1.7 Financial Analysis
10.1.8 SWOT Analysis
10.2 Poseida Therapeutics, Inc .
10.3 Nanjing Beiheng Biological Technology Co., Ltd .
10.4 NantCell, Inc .
10.5 GC Cell Corp
10.6 Bristol Mayer Squibb Company
10.7 Compugen LTD
11 Future Trends
12 Global Allogenic CAR-T Cell Market Landscape (Additional Insight)*
12.1 Global Allogenic CAR-T Cell: Developers Landscape
12.1.1 Analysis by Year of Establishment
12.1.2 Analysis by Company Size
12.1.3 Analysis by Region
12.2 Global Allogenic CAR-T Cell: Product Landscape
12.2.1 Analysis by Product Type
12.2.2 Analysis by Technology
12.2.3 Analysis by Application
*Additional insights are not provided in the standard report.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.